نص مكالمة أرباح Dr. Reddy's Laboratories Limited (RDY) للربع الثاني من عام 2027

Dr. Reddy's Laboratories hosted its second-quarter fiscal earnings call to review financial results and strategic milestones with market stakeholders. Company leadership addressed pricing pressures in core generic markets alongside growth opportunities in biosimilars and proprietary products. The discussion covered key regulatory filings, manufacturing compliance updates, and R&D pipeline advancements across international jurisdictions. Analysts probed management on margin trajectories in the face of rising input costs and competitive landscape shifts. The pharmaceutical player continues to prioritize geographic expansion and portfolio diversification to drive sustainable revenue growth. Strong execution in complex generic drug launches remains a primary pillar for future profitability.